FABP7 has also been shown to be highly expressed in NSCLC patient tumor cells, and studies in NSCLC cell lines indicate that FABP7 exerts prometastatic effects via impaired β-catenin degradation leading to Wnt hyperactivation (9). The gene discussed is FABP7; the disease is neoplasm.